BCL2 and lung cancer: We here provided evidence to support the previous report, indicating that a decrease in miR-184 by E6 oncoprotein confers cisplatin resistance in lung cancer cells and unfavorable chemotherapeutic response in NSCLC patients due to increasing Bcl-2 expression.